These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 32120461)

  • 1. Association between visceral adiposity index, hirsutism and cardiometabolic risk factors in women with polycystic ovarian syndrome: A cross-sectional study.
    Fonseka S; Subhani B; Wijeyaratne CN; Gawarammana IB; Kalupahana NS; Ratnatunga N; Rosairo S; Vithane KP
    Ceylon Med J; 2019 Sep; 64(3):111-117. PubMed ID: 32120461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
    Durmus U; Duran C; Ecirli S
    J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
    Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
    Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
    Anik Ilhan G; Yildizhan B; Pekin T
    Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome].
    Roa Barrios M; Arata-Bellabarba G; Valeri L; Velázquez-Maldonado E
    Endocrinol Nutr; 2009 Feb; 56(2):59-65. PubMed ID: 19627713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY.
    Xie X; Li Q; Zhang L; Ren W
    Endocr Pract; 2018 Jan; 24(1):33-39. PubMed ID: 29144802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome.
    Oh JY; Sung YA; Lee HJ
    Obesity (Silver Spring); 2013 Aug; 21(8):1690-4. PubMed ID: 23585246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profile in women with polycystic ovary syndrome across adult life.
    Echiburú B; Crisosto N; Maliqueo M; Pérez-Bravo F; de Guevara AL; Hernández P; Cavada G; Rivas C; Clavel A; Sir-Petermann T
    Metabolism; 2016 May; 65(5):776-782. PubMed ID: 27085784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome.
    Brończyk-Puzoń A; Jagielski P; Kulik-Kupka K; Koszowska A; Nowak J; Zubelewicz-Szkodzińska B
    Adv Clin Exp Med; 2017 Aug; 26(5):825-828. PubMed ID: 29068579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome.
    Androulakis II; Kandaraki E; Christakou C; Karachalios A; Marinakis E; Paterakis T; Diamanti-Kandarakis E
    Clin Endocrinol (Oxf); 2014 Sep; 81(3):426-31. PubMed ID: 24601936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral Adiposity Index as an Indicator for Menstrual Disturbance, Hormonal and Metabolic Dysfunction in Polycystic Ovarian Syndrome.
    Sharma P; Sarkar A; Kaur H; Gupta U; Kumar B
    Cureus; 2022 Sep; 14(9):e29796. PubMed ID: 36340542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.
    Amato MC; Guarnotta V; Forti D; Donatelli M; Dolcimascolo S; Giordano C
    Hum Reprod; 2013 Jul; 28(7):1919-28. PubMed ID: 23592224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of measuring anthropometric and atherogenic indices in patients with polycystic ovary syndrome.
    Uysal E; Tammo O; Soylemez E; Incebıyık M; Filiz D; Alci M
    BMC Endocr Disord; 2024 Aug; 24(1):160. PubMed ID: 39198818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Visceral Adiposity Index as Predictor of Metabolic Syndrome in Obese and Nonobese Women with Polycystic Ovary Syndrome.
    de Medeiros SF; de Medeiros MAS; Barbosa BB; Yamamoto MMW
    Metab Syndr Relat Disord; 2021 Feb; 19(1):18-25. PubMed ID: 32845813
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
    Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
    Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
    Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
    Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls.
    Glintborg D; Petersen MH; Ravn P; Hermann AP; Andersen M
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1235-1243. PubMed ID: 27529295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.